Search results for "Antimanic Agents"

showing 10 items of 12 documents

Cerebellar parcellation in schizophrenia and bipolar disorder

2019

International audience; Objective: The cerebellum is involved in cognitive processing and emotion control. Cerebellar alterations could explain symptoms of schizophrenia spectrum disorder (SZ) and bipolar disorder (BD). In addition, literature suggests that lithium might influence cerebellar anatomy. Our aim was to study cerebellar anatomy in SZ and BD, and investigate the effect of lithium.Methods: Participants from 7 centers worldwide underwent a 3T MRI. We included 182 patients with SZ, 144 patients with BD, and 322 controls. We automatically segmented the cerebellum using the CERES pipeline. All outputs were visually inspected.Results: Patients with SZ showed a smaller global cerebellar…

AdultMalePathologymedicine.medical_specialtyCerebellumBipolar DisordercerebellumLithium (medication)[INFO.INFO-IM] Computer Science [cs]/Medical ImagingCerebellar Gray MatterCerebellar CortexYoung Adult03 medical and health sciences0302 clinical medicineAntimanic Agents[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansMedicineBipolar disorderbusiness.industrysegmentationCognitionMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030227 psychiatryPsychiatry and Mental healthmedicine.anatomical_structurenervous systemMulticenter studylithiumSchizophreniaparcellationLithium CompoundsSchizophreniaFemalebusiness030217 neurology & neurosurgerymedicine.drugSchizophrenia spectrumActa Psychiatrica Scandinavica
researchProduct

Peripheral Oxidative Stress Markers in Patients with Bipolar Disorder during Euthymia and in Siblings.

2020

Aims:Oxidative stress is increased during the acute phases of bipolar disorder (BD). Our aim here was to analyze oxidative stress biomarkers in patients with BD during euthymia and their siblings.Method:A cross-sectional study was performed in euthymic patients with BD-I (n=48), unaffected siblings (n=23) and genetically unrelated healthy controls (n=21). Protein carbonyl content (PCC), total antioxidant capacity (TRAP), lipid peroxidation (TBARS) and uric acid were measured as biomarkers of oxidative stress in blood.Results:The antioxidant capacity (TRAP) was lower (p<0.001) in patients with BD compared to their siblings and controls, whereas no differences were observed in PCC, TBARS o…

AdultMalemedicine.medical_specialtyBipolar DisorderEndocrinology Diabetes and MetabolismProtein Carbonyl Contentmedicine.disease_causeThiobarbituric Acid Reactive SubstancesLipid peroxidationProtein Carbonylation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAntimanic AgentsInternal medicineTBARSImmunology and AllergyMedicineHumansBipolar disorderValproic Acidbusiness.industrySiblingsValproic AcidMiddle Agedmedicine.disease030227 psychiatryUric AcidOxidative StressEndocrinologyCross-Sectional StudieschemistryCase-Control StudiesBiomarker (medicine)Uric acidFemaleLipid Peroxidationbusiness030217 neurology & neurosurgeryOxidative stressBiomarkersmedicine.drugEndocrine, metabolicimmune disorders drug targets
researchProduct

Clinical factors leading to lamotrigine prescription in bipolar outpatients: Subanalysis of the SIN-DEPRES study

2012

Abstract Background The use of lamotrigine is a point of discrepancy among the diverse guidelines published on the management of bipolar disorder (BD). Evidence supporting the long-term efficacy is reasonably robust. Nonetheless, the effectiveness of lamotrigine in acute treatment is vigorously debated and it is unclear how this drug is used in routine clinical practice. This subanalysis of the SIN-DEPRES study was designed to understand the clinical profile of bipolar patients receiving lamotrigine. Methods In this prospective national multicenter study, 652 patients with clinically stable bipolar I and II disorder were recruited. Clinical assessments included sociodemographic and clinical…

AdultMalemedicine.medical_specialtyBipolar DisorderLamotrigineLamotrigineLogistic regressionBipolar II disorderAntimanic AgentsRating scaleInternal medicineOutpatientsmedicineHumansProspective StudiesBipolar disorderMedical prescriptionPsychiatryDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderTriazinesbusiness.industryMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologyClinical Global ImpressionRegression AnalysisFemaleGuideline Adherencebusinessmedicine.drugJournal of Affective Disorders
researchProduct

Lithium prevents grey matter atrophy in patients with bipolar disorder: an international multicenter study

2020

AbstractBackgroundLithium (Li) is the gold standard treatment for bipolar disorder (BD). However, its mechanisms of action remain unknown but include neurotrophic effects. We here investigated the influence of Li on cortical and local grey matter (GM) volumes in a large international sample of patients with BD and healthy controls (HC).MethodsWe analyzed high-resolution T1-weighted structural magnetic resonance imaging scans of 271 patients with BD type I (120 undergoing Li) and 316 HC. Cortical and local GM volumes were compared using voxel-wise approaches with voxel-based morphometry and SIENAX using FSL. We used multiple linear regression models to test the influence of Li on cortical an…

AdultMalemedicine.medical_specialtyBipolar DisorderLithium (medication)[SDV]Life Sciences [q-bio]UrologyGrey matterGyrus CinguliHippocampus03 medical and health sciences0302 clinical medicineAtrophyAntimanic AgentsmedicineHumansIn patientBipolar disorderGray MatterPathologicalApplied PsychologyComputingMilieux_MISCELLANEOUSGrey matter atrophybusiness.industryConfoundinggrey matter volumeMiddle Agedmedicine.diseaseMagnetic Resonance ImagingTemporal Lobe3. Good health030227 psychiatryPsychiatry and Mental healthmedicine.anatomical_structurelithiumCase-Control StudiesLithium CompoundsFemaleAtrophybusiness030217 neurology & neurosurgeryMRImedicine.drug
researchProduct

Comparative neurocognitive effects of lithium and anticonvulsants in long-term stable bipolar patients

2015

Background: The aim of choosing a mood-stabilizing drug (lithium or anticonvulsants) or a combination of them with minimal neurocognitive effects is to stimulate the development of criteria for a therapeutic adequacy, particularly in Bipolar Disorder (BD) patients who are clinically stabilized. Method: Three groups of BD patients were established according to their treatment: (i) lithium monotherapy (n=29); (ii) lithium together with one or more anticonvulsants (n=28); and (iii) one or more anticonvulsants (n=16). A group of healthy controls served as the control (n=25). The following tests were applied: Wechsler Adult Intelligence Scale, Trail Making Test, Wechsler Memory Scale, Rey Comple…

AdultMalemedicine.medical_specialtyWechsler Memory ScaleBipolar DisorderTrail Making TestNeuropsychological TestsAudiologyExecutive FunctionYoung Adult03 medical and health sciences0302 clinical medicineVisual memoryWisconsin Card Sorting TestAntimanic AgentsmedicineHumansAttentionWorking memoryWechsler Adult Intelligence ScaleMiddle AgedExecutive functions030227 psychiatryPsychiatry and Mental healthClinical PsychologyMemory Short-TermLithium CompoundsAnticonvulsantsDrug Therapy CombinationFemaleCognition DisordersPsychologyNeurocognitive030217 neurology & neurosurgeryClinical psychologyJournal of Affective Disorders
researchProduct

Sexual Dysfunction and Mood Stabilizers in Long-Term Stable Patients With Bipolar Disorder.

2020

Abstract Background In addition to factors intrinsic to bipolar disorder (BD), sexual functioning (SF) can be affected by extrinsic causes, such as psychotropic drugs. However, the effect of mood stabilizers on SF and quality of life (QoL) is an underexplored research area. Aim To analyze SF in BD outpatients in euthymia for at least 6 months treated only with mood stabilizers and the association between SF and QoL. Methods A multicenter cross-sectional study was conducted in 114 BD outpatients treated with (i) lithium alone (L group); (ii) anticonvulsants alone (valproate or lamotrigine; A group); (iii) lithium plus anticonvulsants (L+A group); or (iv) lithium plus benzodiazepines (L+B gro…

Bipolar DisorderUrologyEndocrinology Diabetes and MetabolismSexual arousalmedia_common.quotation_subject030232 urology & nephrologyOrgasmLamotrigine03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeAntimanic AgentsMedicineHumansBipolar disordermedia_commonAged030219 obstetrics & reproductive medicinebusiness.industrymedicine.diseasePsychiatry and Mental healthSexual desireSexual dysfunctionMoodCross-Sectional StudiesReproductive MedicineQuality of LifeAnticonvulsantsFemalemedicine.symptombusinessClinical psychologymedicine.drugAntipsychotic AgentsThe journal of sexual medicine
researchProduct

Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Resul…

2017

Patients with bipolar disorder (BD) do not always achieve full remission between episodes. Subthreshold symptoms (depressive, manic or mixed) represent a major cause of relapse and disability in these patients. Immediate release (IR) and extended release (XR) formulations of quetiapine are both indicated for short and long-term treatment of BD. The aim of this study was to evaluate the efficacy of quetiapine XR vs placebo in subthreshold symptomatology when added to previous mood stabilizer treatment. A pilot phase IIIB, multicentre, prospective, placebo controlled, randomized, double blinded study of 12 weeks follow-up was performed (NCT01197846). Patients were randomized to quetiapine XR …

MaleBipolar Disorder*Bipolar disorderPilot Projectslaw.invention0302 clinical medicineRandomized controlled triallawAntimanic AgentsAmbulatory CarePharmacology (medical)*QuetiapineMood stabilizerMiddle AgedSubthreshold symptomsPsychiatry and Mental healthTreatment OutcomeNeurologyDrug Therapy CombinationFemalemedicine.symptomPsychologySomnolencemedicine.drugAdultmedicine.medical_specialtyAdolescentmedicine.drug_classBipolar disorderPlacebo03 medical and health sciencesQuetiapine FumarateYoung AdultDouble-Blind MethodInternal medicinemedicineHumans*Subthreshold symptomsBipolar disorderPsychiatryAdverse effectBiological PsychiatryAgedPharmacologyPsychiatric Status Rating ScalesQuetiapineBody Weightmedicine.disease030227 psychiatryMoodDelayed-Action PreparationsQuetiapineNeurology (clinical)030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Oral lichenoid drug reaction by lithium in a patient with bipolar disorder

2005

Bipolar disorder (BD) is a psychiatric disease characterized by recurrent and alternated episodes of depression and mania. For the treatment of BD, anticonvulsants drugs as lithium, carbamazepine and oxcarbazepine can be used. These drugs can be associated with potential adverse effects: weight gain, tremors, thyroid abnormalities, and cognitive, gastrointestinal, cardiac or dermatological problems. We describe a case of BD with oral lichenoid drug reaction probably because of the mood stabilizers.

MaleCancer Researchmedicine.medical_specialtyBipolar DisorderLichenoid EruptionsLithium (medication)antipsychotics bipolar disorders drug reaction lichenoid lesions lithium therapyPathology and Forensic Medicinechemistry.chemical_compoundLithium CarbonateAntimanic Agentsmental disordersmedicineHumansBipolar disorderOxcarbazepineAdverse effectbusiness.industryLithium carbonateCarbamazepineMiddle Agedmedicine.diseaseDermatologySurgeryOtorhinolaryngologychemistryLichenoid eruptionPeriodonticsOral Surgerymedicine.symptomMouth DiseasesbusinessManiamedicine.drugJournal of Oral Pathology and Medicine
researchProduct

Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgeni…

2007

The molecular mechanism of action of the mood stabilizer lithium is assumed to involve changes in gene expression leading to neuronal adaptation. The transcription factor CREB (cAMP-responsive element binding protein) regulates the expression of many genes and has been implicated in important brain functions and the action of psychogenic agents. We here investigated the effect of lithium on cAMP-responsive element (CRE)/CREB-mediated gene transcription in the brain, using transgenic reporter mice that express the luciferase reporter gene under the control of four copies of the rat somatostatin gene promoter CRE. Chronic (21 days) but not acute (24 h) treatment with lithium (7.5 mmol/kg) sig…

MaleTranscriptional ActivationBipolar DisorderTransgeneDown-RegulationMice TransgenicCREBDrug Administration Schedule03 medical and health sciencesGlycogen Synthase Kinase 3Mice0302 clinical medicineGSK-3Transcription (biology)Antimanic AgentsGenes ReporterGene expressionAnimalsPhosphorylationProtein kinase ACyclic AMP Response Element-Binding ProteinSocial BehaviorTranscription factor030304 developmental biologyPharmacology0303 health sciencesReporter genebiologyBehavior AnimalBrainMolecular biologyUp-RegulationPsychiatry and Mental healthDisease Models AnimalGene Expression RegulationChronic Diseasebiology.proteinLithium Compounds030217 neurology & neurosurgeryStress PsychologicalAdenylyl CyclasesSignal TransductionNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-…

2016

ObjectivesTo meta-analytically summarize lamotrigine’s effectiveness and safety in unipolar and bipolar depression.MethodsWe conducted systematic PubMed and SCOPUS reviews (last search =10/01/2015) of randomized controlled trials comparing lamotrigine to placebo or other agents with antidepressant activity in unipolar or bipolar depression. We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs).ResultsEighteen studies (n=2152, duration=9.83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation …

Olanzapinemedicine.medical_specialtyBipolar DisorderLithium (medication)Bipolar depressionBipolar depression bipolar disorder lamotrigine major depressive disorder trials unipolar depressionCitalopramLithiumCitalopramLamotrigineLamotriginePlaceboBipolar depression; bipolar disorder; lamotrigine; major depressive disorder; trials; unipolar depressionBenzodiazepines03 medical and health sciences0302 clinical medicineAntimanic AgentsFluoxetineInternal medicinemedicineHumansBipolar disorderunipolar depressionPsychiatryDepressive Disorder MajorFluoxetinemajor depressive disorderDepressionTriazinesbusiness.industrytrialsmedicine.diseaseAntidepressive Agents030227 psychiatryDrug CombinationsPsychiatry and Mental healthVitamin B ComplexMajor depressive disorderAnticonvulsantsNeurology (clinical)businessInositol030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drug
researchProduct